PDPaweł Dec

Paweł Dec

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paweł Dec has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long Non-Coding RNAs SNHG7, SNHG12, and SNHG14 in Rheumatoid Arthritis: Clinical and In Silico Analysis

    by Michał Czerewaty, Paweł Dec, Krzysztof Safranow, Andrzej Pawlik

    Rheumatoid arthritis (RA) is an autoimmune disease with a complex pathogenesis. It has been shown that epigenetic modifications can influence the differentiation and function of many immune system cells involved in the pathogenesis of RA. Important epigenetic factors include non-coding RNAs, such as long non-coding RNAs (lncRNAs). Non-coding RNAs can influence numerous immune processes in RA. This study aimed to evaluate the expression of lncRNAs SNHG7, SNHG12, and SNHG14 in the synovial membranes of patients with RA and to correlate these results with selected clinical parameters of the disease. This study included 46 patients diagnosed with RA and 67 healthy individuals as the control group. The expression levels of the lncRNAs SNHG7, SNHG12, and SNHG14 in synovial membranes in patients with RA were statistically higher than those in the control group. The synovial expression of SNHG14 showed a statistically significant negative correlation with C-reactive protein values. There were no statistically significant correlations between synovial expression of SNHG7, SNHG12, and clinical parameters. The study results suggest that lncRNAs may potentially play a role in the development of RA.

  • Open Access

    The Role of Fc-like Receptor 3 in the Pathophysiology of Rheumatoid Arthritis

    by Paweł Dec, Paulina Plewa, Adam Kubisa, Andrzej Pawlik

    The pathogenesis of rheumatoid arthritis involves a complex interplay of genetic predisposition, environmental factors, and autoimmune mechanisms that lead to chronic inflammation of the synovial membrane. Fc-like receptor 3 (FcRL3) is a receptor encoded by the FCRL3 gene, located on the long arm of chromosome 1 at 1q23.1. Polymorphisms in the promoter region of FCRL3, rather than elsewhere in the gene, primarily affect the level of protein expression, which is of clinical significance. Understanding the structure of FcRL3, particularly in the context of genetic variants, is therefore important for elucidating the pathogenesis of autoimmune diseases. Detailed knowledge of the molecular architecture of immune receptors such as FcRL3 is also essential for advancing our understanding of immune function and for guiding the development of targeted therapeutic strategies in autoimmune disease. In this article, we discuss the role of FcRL3 in the pathophysiology and potential therapy of rheumatoid arthritis.


  • Open Access

    DNA and RNA Methylation in Rheumatoid Arthritis—A Narrative Review

    by Kajetan Kiełbowski, Estera Bakinowska, Anna Gorący-Rosik, Karolina Figiel, Roksana Judek, Jakub Rosik, Paweł Dec, Andrzej Modrzejewski, Andrzej Pawlik

    Rheumatoid arthritis (RA) is a progressive autoimmune disease leading to structural and functional joint damage and, eventually, to physical disability. The pathogenesis of the disease is highly complex and involves interactions between fibroblast-like synoviocytes (FLSs) and immune cells, which stimulate the secretion of pro-inflammatory factors, leading to chronic inflammation. In recent years, studies have demonstrated the importance of epigenetics in RA. Specifically, epigenetic alterations have been suggested to serve as diagnostic and treatment biomarkers, while epigenetic mechanisms are thought to be involved in the pathogenesis of RA. Epigenetic regulators coordinate gene expression, and in the case of inflammatory diseases, they regulate the expression of a broad range of inflammatory molecules. In this review, we discuss current evidence on the involvement of DNA and RNA methylation in RA.


  • Open Access

    Recent Advances in the Use of Stem Cells in Tissue Engineering and Adjunct Therapies for Tendon Reconstruction and Future Perspectives

    by Paweł Dec, Małgorzata Żyłka, Piotr Burszewski, Andrzej Modrzejewski, Andrzej Pawlik

    Due to their function, tendons are exposed to acute injuries. This type of damage to the musculoskeletal system represents a challenge for clinicians when natural regeneration and treatment methods do not produce the expected results. Currently, treatment is long and associated with long-term complications. In this review, we discuss the use of stem cells in the treatment of tendons, including how to induce appropriate cell differentiation based on gene therapy, growth factors, tissue engineering, proteins involved in regenerative process, drugs and three-dimensional (3D) structures. A multidirectional approach as well as the incorporation of novel components of the therapy will improve the techniques used and benefit patients with tendon injuries in the future.


  • Open Access

    The Role of Omentin-1 in Cancers Development and Progression

    by Paweł Dec, Agata Poniewierska-Baran, Andrzej Modrzejewski, Andrzej Pawlik

    Adipose tissue serves as an energy store and is also an active endocrine organ, exerting activity that influences obesity-related processes through the production of regulatory proteins called adipokines or adipocytokines. Adipokines play important direct and indirect roles in the pathogenesis of insulin resistance, the regulation of local and systemic inflammatory processes, and related metabolic complications. There have been an increasing number of studies showing the relationship between some adipokines and carcinogenesis. This work reviews the current literature concerning the effects of omentin-1 on carcinogenesis.


  • Open Access

    The Role of Adipokines in the Pathogenesis of Psoriasis

    by Kajetan Kiełbowski, Estera Bakinowska, Piotr Ostrowski, Bartłomiej Pala, Ewa Gromowska, Klaudia Gurazda, Paweł Dec, Andrzej Modrzejewski, Andrzej Pawlik

    Psoriasis is a chronic and immune-mediated skin condition characterized by pro-inflammatory cytokines and keratinocyte hyperproliferation. Dendritic cells, T lymphocytes, and keratinocytes represent the main cell subtypes involved in the pathogenesis of psoriasis, while the interleukin-23 (IL-23)/IL-17 pathway enhances the disease progression. Human adipose tissue is an endocrine organ, which secretes multiple proteins, known as adipokines, such as adiponectin, leptin, visfatin, or resistin. Current evidence highlights the immunomodulatory roles of adipokines, which may contribute to the progression or suppression of psoriasis. A better understanding of the complexity of psoriasis pathophysiology linked with adipokines could result in developing novel diagnostic or therapeutic strategies. This review aims to present the pathogenesis of psoriasis and the roles of adipokines in this process.


  • Open Access

    The Role of MicroRNA in the Pathogenesis of Diabetic Nephropathy

    by Joanna Szostak, Anna Gorący, Damian Durys, Paweł Dec, Andrzej Modrzejewski, Andrzej Pawlik

    Diabetic nephropathy is one of the most common and severe complications of diabetes mellitus, affecting one in every five patients suffering from diabetes. Despite extensive research, the exact pathogenesis of diabetic nephropathy is still unclear. Several factors and pathways are known to be involved in the development of the disease, such as reactive oxygen species or the activation of the renin–angiotensin–aldosterone system. The expression of those proteins might be extensively regulated by microRNA. Recent research suggests that in diabetic nephropathy patients, the profile of miRNA is significantly changed. In this review, we focus on the actions of miRNA in various pathways involved in the pathogenesis of diabetic nephropathy and the clinical usage of miRNAs as biomarkers and therapeutic targets.


  • Open Access

    Existing and Novel Biomaterials for Bone Tissue Engineering

    by Paweł Dec, Andrzej Modrzejewski, Andrzej Pawlik

    The treatment of bone defects remains one of the major challenges in modern clinical practice. Nowadays, with the increased incidence of bone disease in an aging population, the demand for materials to repair bone defects continues to grow. Recent advances in the development of biomaterials offer new possibilities for exploring modern bone tissue engineering strategies. Both natural and synthetic biomaterials have been used for tissue repair. A variety of porous structures that promote cell adhesion, differentiation, and proliferation enable better implant integration with increasingly better physical properties. The selection of a suitable biomaterial on which the patient’s new tissue will grow is one of the key issues when designing a modern tissue scaffold and planning the entire treatment process. The purpose of this article is to present a comprehensive literature review of existing and novel biomaterials used in the surgical treatment of bone tissue defects. The materials described are divided into three groups—organic, inorganic, and synthetic polymers—taking into account current trends. This review highlights different types of existing and novel natural and synthetic materials used in bone tissue engineering and their advantages and disadvantages for bone defects regeneration.